SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys latest quarterly report is driving attention: shares rose despite revenue and EPS misses as traders focused on premium-subscriber growth, improved gross margin, and a stronger profit outlook. The move has surprised some investors, while skeptics point to rising expenses and weaker free cash flow.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS, its established therapy for the same disease. Traders are divided over how much the rival will threaten PAPZIMEOS, pointing to Precigens first-mover and full-approval position while questioning Inovios accelerated-approval status, reimbursement path, and ability to commercialize.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Attention is centered on Compounds institutional push: traders cite a new institutional market launch, treasury-funded upgrades, leadership changes and plans involving tokenized assets. Bulls see potential for stronger DeFi adoption, while skeptics point to COMPs lagging price action and question whether the initiatives will translate into token demand.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is in focus as traders use the equal-weight S&P 500 to gauge whether market gains are spreading beyond mega-cap technology, with many pointing to rotation into broader, non-tech stocks. Others warn that recent weakness and divergence from cap-weighted indexes may signal fading breadth rather than a healthy broadening rally.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs stronger-than-expected quarterly results and raised full-year outlook, supported by improving HEYDUDE sales and steady demand for its namesake brand, have driven a sharp share-price rally. Traders are debating whether the momentum can continue, with some bullish on the turnaround and others anticipating profit-taking or a pullback.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off sharply after its quarterly results beat expectations but its next-quarter outlook pointed to slower organic growth, disappointing investors focused on deceleration. Traders are divided between treating the drop as a buying opportunity and worrying that slowing growth outweighs the longer-term AI communications opportunity.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Reported MoneyGram/Stellar payroll integration and other expansion news, including Robinhood Chain and Germany-related developments, are fueling attention around Zebec. Bulls see partnerships and payroll adoption as potential drivers of ZBCN demand, while skeptics question whether usage and token value capture are translating into stronger price performance.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,020,742,700.022444 with 95,020,750,177.733244 in circulation. The last known price of TRON is 0.3287714 USD and is down -6.58 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,904,975,878.16 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention amid a price pullback, with traders debating whether its relative resilience and role in stablecoin payments outweigh its recent weakness. Technical posts focus on support and consolidation, while some holders praise the networks steady performance and others complain that the token has been stagnant.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,763,011.6159 in circulation. The last known price of Algorand is 0.09537939 USD and is up 2.17 over the last 24 hours. It is currently trading on 586 active market(s) with $72,099,657.31 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

A modest ALGO rebound and renewed attention around its new CEO are prompting bullish calls for a recovery, with some traders also pointing to altseason and Algorands quantum-resistant technology. Others remain skeptical, arguing that past rallies have faded and the token remains deeply below prior highs; no single confirmed catalyst dominates the discussion.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 earnings beat estimates, with resilient payment and cross-border activity drawing attention, but its outlook for slower growth and cost pressures tempered the response. Traders are split between viewing the quarter as evidence of a durable business and seeing the stocks run-up as leaving little room for an earnings beat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AXSM is drawing attention amid a steep selloff ahead of its Q3 results, with investors focused on whether Auvelitys Alzheimers-agitation launch is translating into prescription and revenue growth and whether commercial spending is delaying profitability. Bulls argue reported scripts may undercount uptake through samples and long-term-care channels, while skeptics point to muted prescription trends and managements silence as reasons for concern.

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

Top 3 Health Care Stocks That Could Blast Off In October

Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.read more...

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market...

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders...

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has a marketread more...

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?

Key PointsAxsome Therapeutics' revenue is growing at a good clip...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>First approved in 2022 as an oral treatment for major depression in adults, Auvelity won a second U.S. clearance in April 2026 for agitation linked to Alzheimer’s dementia.</li><li>Management has said peak annual sales for Auvelity could reach $8 billion, split roughly evenly between depression and Alzheimer’s agitation.</li><li>COO Mark Jacobson recently highlighted that Auvelity has no boxed warning for higher death risk in people with dementia, a label that limits the only other approved branded option.</li></ul><p><br>Shares of Axsome Therapeutics (AXSM) rose 6% on Friday after Mizuho analyst Graig Suvannavejh said August prescription data pointed to a strong start for the drug’s newest use.</p><p>Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, he said new prescriptions rose 32% from July, and total prescriptions rose 34%. The stock is now on track to clock its best day since late July, if gains hold.</p><p>“While still early days in the launch, this appears highly indicative of a strong start for Auvelity in ADA,” he wrote. Suvannavejh rates the stock ‘Outperform’ with a $316 price target, implying a potential upside of about 50% from the stock’s last closing price.</p><h2 class="st-heading-2">Why The New Use Matters</h2><p>Auvelity is Axsome’s main product. First approved in 2022 as an oral treatment for major depression in adults, it won a second U.S. clearance in April 2026 for agitation linked to Alzheimer’s dementia — the first non-antipsychotic approved for that condition. Axsome began selling into the new indication in June.</p><p>The Alzheimer’s launch is central to the company’s finances. Auvelity generated $180.3 million in second-quarter sales, up 51% from a year earlier, and made up most of Axsome’s $218.4 million in product revenue. Management has said peak annual sales could reach $8 billion, split roughly evenly between depression and Alzheimer’s agitation.</p><p>Axsome also sells Sunosi for excessive daytime sleepiness tied to narcolepsy or sleep apnea, and Symbravo for acute migraine. Both add sales but remain far smaller than Auvelity.</p><h2 class="st-heading-2">What Management Is Seeing</h2><p>At Cantor Fitzgerald’s conference on Thursday, executives said early doctor feedback matches the trial data: agitation eases quickly, and the drug is well tolerated in a frail group.</p><p>COO Mark Jacobson highlighted that Auvelity has no boxed warning for higher death risk in people with dementia, a label that limits the only other approved branded option, an antipsychotic. That difference, he said, is already generating interest, with the commercial impact expected to build through year-end.</p><p>CFO Nick Pizzie said new prescriptions for patients 65 and older rose 126% after the Alzheimer’s launch. That older Medicare group was about 19% of new starts before approval and is now more than 30%. Most early use is coming from community doctors; nursing homes take longer to bring online, he added.</p><h2 class="st-heading-2">What Investors Will Watch Next</h2><p>The next test for AXSM is whether the August jump in starter doses turns into ongoing use of the full maintenance dose and shows up in third-quarter results, expected in early November. Later this year, Axsome is also due to report late-stage data on solriamfetol — Sunosi’s active ingredient — in binge-eating disorder. It has also started a late-stage study of Auvelity’s compound as a smoking-cessation treatment. A separate narcolepsy candidate, AXS-12, has an FDA decision date of May 1, 2027.</p><h2 class="st-heading-2">How Did AXSM Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AXSM stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has gained 22% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-on-track-for-worst-week-since-last-fall-as-fda-filing-date-for-skin-disease-drug-draws-near/cZtXYWDRBbJ">MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August. 

Vanguard Small Cap ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXSM News